deaths (OS)

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 4 0.74 [0.56; 0.97], 2 RCTs, I2=51% conclusive
moderate degree of certainty